Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and
semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known
medicine, which is already used by doctors to treat type 2 diabetes in many countries. It
also helps with weight loss and may reduce liver damage, and so prevent future liver
complications. It works in a different way to NNC0194 0499. The 2 medicines may work better
together than on their own.
The study will also look at a combination of semaglutide and another weight-loss medicine
called NNC0174-0833, which may be another treatment option for NASH.
Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of
the medicines and a placebo OR 2 placebo injections. Which treatment participants get is
decided by chance. A placebo is a dummy medicine which looks like the real medicine but
doesn't contain any active medicine.
The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone
calls with the study doctor.
Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start
(if participants have not had a biopsy recently) and one at the end of the study treatment.
Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant
during the study period.
Phase
Phase 2
Funding Agency/Sponsor
Industry
Disease
NASH (Non-Alcoholic SteatoHepatitis)
Enrollment Eligibility
Inclusion Criteria:
- Aged greater than or equal to 18 years at the time of signing informed consent. In
Republic of Korea, subjects must be aged greater than or equal to 19 years. In Japan,
subjects must be aged greater than or equal to 20 years. In Singapore, subjects must
be aged greater than or equal to 21 years.
- Histological evidence of NASH based on a central pathologist evaluation of the
baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained
within 180 days prior to Visit 1.
- Histological evidence of fibrosis stage 2, 3 or 4 according to the NASH CRN
classification based on a central pathologist evaluation of the baseline liver biopsy.
- Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS) greater
than or equal to 4 for subjects with F2/F3 or greater than or equal to 3 for subjects
with F4 based on a central pathologist evaluation of the baseline liver biopsy. All
subjects must have a score of 1 or more in steatosis, lobular inflammation and
hepatocyte ballooning.
Exclusion Criteria:
- Documented causes of chronic liver disease other than NAFLD.
- Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known
presence of HCV RNA or HBsAg within 2 years of screening (V2A).
- Presence or history of ascites more than grade 1, variceal bleeding, hepatic
encephalopathy, spontaneous bacterial peritonitis or liver transplantation at V2A.
- For subjects with F4, presence or history of gastro-oesophageal varices more than or
equal to grade 2 at V3. An oesophagogastroduodenoscopy performed no more than 52 weeks
prior to V3 must be available at V3.
- Known or suspected excessive consumption of alcohol (more than 20 g/day for women or
more than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use
Disorders Identification Test (AUDIT questionnaire)).
- Treatment with vitamin E (at doses more than or equal to 800 IU/day) or pioglitazone
or medications approved for the treatment of NASH which has not been at a stable dose
in the opinion of the investigator in the period from 90 days prior to V2A. In
addition, for subjects with a historical liver biopsy taken more than 90 days prior to
V2A, treatment should be at a stable dose in the opinion of the investigator from time
of biopsy until V2A.
- Treatment with GLP-1 RAs within 90 days prior to V2A. Subjects with a historical liver
biopsy taken more than 90 days prior to V2A are excluded if they receive treatment
with GLP-1 RAs from time of biopsy until V2A.
- Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering
medication or weight loss medication not stable in the opinion of the investigator in
the period from 90 days prior to V2A. In addition, for subjects with a historical
liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable
dose in the opinion of the investigator from time of biopsy until V2A.